Treatments for lung cancer have historically been considered “one-size-fits-all” The development of Precision Oncology, however, has led to increased recognition of non-small cell lung cancer (NSCLC) as a molecularly complex amalgam of diseases with differing outcomes. The 2023 Precision Oncology Summit was held in San Francisco on October 7 th and 8 th , focused on actionable strategies addressing personalized treatment to improve outcomes of patient with lung cancer. This manuscript summarizes the discussion and key learning points from the precision medicine clinical science symposium in NSCLC, including the latest translational science, and clinical applications updates.
No takes yet. Share an insight, caveat, or question.
Riaño et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: